announcedmandatorydisease-specific

GLOBE

Global Benchmark for Efficient Drug Pricing Model

The Global Benchmark for Efficient Drug Pricing (GLOBE) Model is a proposed mandatory model that would assess a rebate for certain drugs payable under Medicare Part B if the prices exceed those paid in economically comparable countries. CMS expects GLOBE would reduce out-of-pocket drug costs for people with Medicare and result in savings to Medicare while preserving or enhancing beneficiaries’ quality of care.

Active Since2026-10-01

Innovation

CMS would use manufacturer rebates when the price of the drug exceeds that of an international benchmark based on what other comparable countries pay.

The Problem

Americans increasingly pay more for medications compared to other countries, potentially putting patients in a difficult position of having to choose between paying for necessary treatments or for other critical expenses of daily living.

The Solution

Under GLOBE, CMS would use manufacturer rebates when the price of the drug exceeds that of an international benchmark based on what other comparable countries pay — making the net cost to Medicare for certain Part B drugs similar to what other comparable countries pay.

Expected Outcomes

GLOBE would lower out-of-pocket costs for people with Medicare, helping ensure they can afford and continue to access certain necessary Part B medications, while preserving or enhancing beneficiaries’ quality of care.

Strategy

GLOBE advances the Innovation Center’s commitment to help people with Medicare live healthier lives while also promoting the sustainability of the Medicare program.

Model Goals

  • Reduce out-of-pocket drug costs for people with Medicare
  • Result in savings to Medicare
  • Preserve or enhance beneficiaries' quality of care
  • Make the net cost to Medicare for certain Part B drugs similar to what other comparable countries pay

Patient Eligibility

People with Medicare receiving certain Part B medications administered in a clinical setting.

  • Must be receiving certain Part B drugs
  • Drugs must be administered in a clinical setting

Provider Eligibility

Care Categories

Clinical Setting Administered Drugs

Cancer therapiesAutoimmune condition treatmentsArthritis treatments

CMS Benchmarks & Thresholds

operational

Reconciliation End Year2,033
Model Duration5
Model Launch Month10
Model End Year2,031
Public Comment Deadline Year2,026
Public Comment Deadline Month2
Public Comment Deadline Day23
Model Launch Year2,026

Is this model right for your organization?

Answer three quick questions about your facility and get matched to the VBC models that fit your profile with verified benchmark context.

Start Your Analysis